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PET/MR Outperforms PET/CT in Suspected Occult Tumors
Tetsuro Sekine, MD, PhD,*† Felipe de Galiza Barbosa, MD,* Bert-Ram Sah, MD,* Cäcilia E. Mader, MD,*
Gaspar Delso, PhD,‡ Irene A. Burger, MD,*§ Paul Stolzmann, MD,*|| Edwin E. ter Voert, MS,*
Gustav K. von Schulthess, MD, PhD,* Patrick Veit-Haibach, MD,*§ and Martin W. Huellner, MD*||
Background: To compare the diagnostic accuracy of PET/MR and PET/CT
in patients with suspected occult primary tumors.
Methods: This prospective study was approved by the institutional review
board. Sequential PET/CT-MR was performed in 43 patients (22 male
subjects; median age, 58 years; range, 20-86 years) referred for suspected
occult primary tumors. Patients were assessed with PET/CT and PET/MR
for the presence of a primary tumor, lymph node metastases, and distant
metastases. Wilcoxon signed-rank test was performed to compare the di-
agnostic accuracy of PET/CT and PET/MR.
Result: According to the standard of reference, a primary lesion was found
in 14 patients. In 16 patients, the primary lesion remained occult. In the re-
maining 13 patients, lesions proved to be benign. PET/MR was superior to
PET/CT for primary tumor detection (sensitivity/specificity, 0.85/0.97 vs
0.69/0.73; P = 0.020) and comparable to PET/CT for the detection of lymph
node metastases (sensitivity/specificity, 0.93/1.00 vs 0.93/0.93; P = 0.157)
and distant metastases (sensitivity/specificity, 1.00/0.97 vs 0.82/1.00;
P = 0.564). PET/CT tended to misclassify physiologic FDG uptake as
malignancy compared with PET/MR (8 patients vs 1 patient).
Conclusions: PET/MRoutperformsPET/CTin theworkup of suspected occult
malignancies. PET/MR may replace PET/CT to improve clinical workflow.
Key Words: PET/MR, PET/CT, oncology, head and neck cancer,
multimodality imaging, cancer of unknown primary, occult tumors
(Clin Nucl Med 2016;00: 00–00)
O ccult tumors may manifest with metastases to lymph nodes orto organs, with paraneoplastic symptoms or with increased
serum tumor markers. Carcinoma of unknown primary (CUP) is
defined as metastatic malignancy whose primary site cannot be
detected at the time of diagnosis.1 Carcinoma of unknown primary
ranks among the top 10 of cancer diagnoses worldwide, accounting
for 3% to 5% of all malignant tumors.1,2 The frequency of CUP di-
agnoses heavily depends on previously performed diagnostic
workup, including cross-sectional imaging. Carcinoma of unknown
primary represents an inhomogeneous group of tumors.1 Prognosis
of patients is generally dismal.1,3,4 To treat CUP patients appropri-
ately, not only information on histopathological features and tumor
markers is important but also knowledge about coexisting metasta-
tic lesions and—most pertinent—about the presumed primary site.
Treatment options vary considerably depending on primary site and
extent of metastatic spread.3 Therefore, whole-body imaging ex-
aminations are considered first choice in the evaluation of patients
with suspected occult malignancies. 18F-fluoro-2-deoxy-D-glucose
(FDG)–PET/CT is one preferred imaging modality because of its
comparably high detectability of primary sites, reaching approxi-
mately 30%.5–8 PET/CT is reimbursed in several countries for this
indication, despite absence of evidence that PET/CT is truly cost-
effective.9,10 Other options would be whole-body CT or MRI.
Although there is currently no agreement on the cross-sectional im-
aging algorithm in the assessment of CUP patients, PET/CT was
shown to be more sensitive and more effective than contrast-
enhanced CT or MR.11,12 In our experience, centers with access
to PET/CT use this tool early on. It is understood that any delay in
the diagnostic workflow may eventually worsen the prognosis of
the patient.
The most recent hybrid imaging modality potentially suitable
for CUP patients is PET/MR.13–18 To date, the diagnostic capability
of PET/MR in occult malignancies has not been studied.
The purpose of this preliminary study was to assess the diag-
nostic accuracy of PET/MR comparedwith PET/CT in patientswith
suspected occult malignancies.
PATIENTS AND METHODS
This prospective study was approved by the institutional re-
view board. All subjects provided signed informed consent before
enrollment. There was financial support by an institutional grant
from GE Healthcare. Only non-GE employees had control of inclu-
sion of data and information that might present a conflict of interest
for those authors who are employees of GE Healthcare. Inclusion
criteria were referral for PET/CT for the assessment of a suspected
occult malignancy between January 2011 and August 2014 and
willingness to undergo an additional MR examination. Exclusion
criteria were contraindications to MRI (eg, implanted medical de-
vices, metallic foreign bodies, severe claustrophobia). According
to these criteria, we enrolled a total of 43 patients (22 male subjects;
median age, 58 years; range, 20–86 years). Detailed patient charac-
teristics are given in Table 1.
Imaging Techniques
All patients underwent PET/CT and MR using a trimodality
PET/CT-MRI system (Discovery PET/CT 690 VCT, Discovery
MR 750w; GE Healthcare, Waukesha, WI). Specifications of this
system have been described previously.14 Patients fasted for at least
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4 hours before the injection of a standard dose of 4.5 MBq/kg of
FDG per kilogram body weight. After an uptake time of 30 minutes,
patients were positioned on the shuttle table in the MR suite, and
MR datasets were acquired (whole-body nonenhanced sequences,
regionalized contrast-enhanced sequences covering the clinically
suspected location of the primary tumor [if applicable; depending,
eg, on location and histopathology of metastases]). In 19 patients,
the intravenously injected amount of contrast medium (Omniscan;
GE Healthcare) was 0.2 mL/kg body weight, using an injection rate
of 1.5 mL/s. The other 24 patients did not receive contrast because
no particular primary site was suspected clinically. After comple-
tion of the MR examination (total MR acquisition time limited to
approximately 25 minutes), coils were removed without patient re-
positioning, and patients were transferred to the PET/CT scanner.
Subsequently (at approximately 60 minutes after FDG injection),
a nonenhanced CT scan and PETemission data were acquired from
the mid-thigh to the vertex of the skull. In the 19 patients mentioned
previously, 70 to 100 mL of iodinated contrast medium (Visipaque
320; GE Healthcare) were injected intravenously at a rate of 3 mL/s
directly after the acquisition of the PET data, to acquire a regional-
ized contrast-enhanced CT exam.
MRI
For image acquisition, radiofrequency coils were used for the
whole body (GEM48-channel AA&PA; GEHealthcare) and for the
head and neck (GEM 20-channel HNU; GE Healthcare), if applica-
ble. MRI used several pulse sequences. Whole-body multi-section
imaging was performed using an axial T1-weighted 3D dual-echo
gradient-echo sequence (TR, 4.3 ms; TE, 1.3/2.6 ms; flip angle,
12 degrees; parallel imaging acceleration factor, 2; voxel size,
1.951.952.60 mm; scan time, 18 seconds per bed; 6 bed acqui-
sition, liver accelerated volume acquisition [LAVA]-Flex; GE
Healthcare), which is identical to the sequence used for attenuation
correction on integrated PET/MR machines. Such a rather short
MR protocolwas previously shown to be diagnostically comparable
to “low-dose” CT.19 Additional regionalized MR pulse sequences
were chosen based on the suspected location of the primary tumor
(head and neck, chest, abdomen), if individual patient history and
referral information allowed for such an assumption. In case of
a suspected head and neck primary, the protocol used was published
previously.20 For a suspected thoracic primary, an axial T2-weighted
sequence with motion correction (periodically rotated overlapping
parallel lines with enhanced reconstruction [PROPELLER]; GE
Healthcare) (TR, 9321 ms; TE, 122 ms; parallel imaging acceler-
ation factor, 3; voxel size, 1.381.384.50 mm; scan time, ap-
proximately 5 minutes; 1 bed acquisition), acquired during free
breathing, and a contrast-enhanced LAVA-Flex sequence were
used. For a suspected intra-abdominal primary, the same sequences
were used. All regionalized protocols took less than 20 minutes of
acquisition time, fitting into the 25 minutes of total MR acquisition
time during the uptake period. The rationale of this approach was to
use MR sequences that could readily be implemented into a PET/
MR protocol on an integrated scanner.21
PET/CT
All CT scans were acquired in breath-hold. The whole-body
scan parameters were as follows: tube voltage of 120 to 140 kV, tube
current with automated dose modulation of 30 to 60 mA/slice, colli-
mation of 64 0.625, pitch of 0.984:1, rotation time of 0.5 seconds,
coverage speed of 78 mm/s, FOVof 50 cm, images with transverse
pixel size of 0.625, and slice thickness of 3.75 mm, reconstructed in
the axial plane. For the regionalized contrast-enhanced CT scan, the
following parameters were different: tube current of 60 to 440 mA/
slice and image slice thickness of 1.25 mm, reconstructed in axial,
coronal, and sagittal plane.
PET datawere acquired in 3D time of flight (TOF) modewith
a scan duration of 2 minutes per bed position, 23% overlap of bed
positions, and an axial FOVof 153 mm. The emission data were
corrected for attenuation using CT and were iteratively recon-
structed (matrix size of 256 256 pixels, 3D TOFordered subset
expectation maximization with 3 iterations and 18 subsets, with
point spread function, 4.7 mm full width at half maximum, 1:4:1
weighted axial filtering).
Image Evaluation
The acquired PET, CT, and MR images were transmitted to a
dedicated review workstation (AdvantageWorkstation, Version 4.6;
GE Healthcare) for the review of PET, CT, and MR images side by
side or in fused/overlay mode (PET/CT; PET/MR).
Four radiologists/nuclear medicine physicians (B.-R.S., F.B.,
C.E.M., and M.W.H.) with 5 to 9 years of experience in PET/CT
TABLE 1. Initial Patient and Tumor Characteristics
No. patients 43
Sex
Male 22 (51%)
Female 21 (49%)
Patient age (median, range) [yr] 58 (20–86)
≥ 60 20 (47%)
< 60 23 (53%)
Initial reason for clinical diagnosis of CUP
Malignant lymphadenopathy, verified by histopathology
Upper cervical 17 (40%)
Mediastinal 4 (9%)
Pelvic 1 (2%)
Other solid organ findings
Neck mass 1 (2%)
Suspected lung metastases 3 (7%)
Suspected liver metastases 4 (9%)
Suspected adrenal metastasis 1 (2%)
Retroperitoneal mass 1 (2%)
Subcutaneous mass 2 (5%)
Pelvic effusion and suspected peritoneal carcinomatosis 1 (2%)
Nonsolid findings
Paraneoplastic symptoms 6 (14%)
Fever of unknown origin and systemic inflammation 1 (2%)
Increased serum tumor marker 1 (2%)
Initial histopathology
Squamous cell carcinoma 17 (40%)
Adenocarcinoma 3 (7%)
Non-small cell carcinoma 1 (2%)
Poorly differentiated carcinoma 1 (2%)
Paraganglioma 1 (2%)
Mucinous carcinoma 1 (2%)
Mucoepidermoid carcinoma 1 (2%)
Not available 18 (42%)
Imaging workup before PET/CT-MR (within 4 months)
Regional CT 16 (37%)
Regional MRI 10 (23%)
Ultrasound 26 (60%)
Endoscopy 15 (30%)
No imaging workup 3 (7%)
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and/or MR reading analyzed the images in random order and were
blinded to all clinical data except the suspected presence and—if
applicable—suspected location of the occult tumor. Readers were
separated into 2 review boards. Review board A interpreted
PET/CT only, and review board B interpreted PET/MR only. An
intraboard consensus decision was reached if the results of the 2
readers were different. To clarify the impact of the PET component
on diagnostic accuracy, and to address the performance of the ana-
tomical imaging components, analyses of PET/CT versus CT, PET/
MR versus MR, and CT versus MR were carried out additionally.
Standard of Reference
The standard of reference consisted of clinical findings in all
patients including intraoperative results and histopathology, if avail-
able, and clinical and imaging follow-up (median, 1204 days; range,
523–1848 days), containing at least one cross-sectional imaging
modality in each patient. If, until the end of follow-up, no primary
tumor had been detected in a patient with a metastasis verified by
histopathology, the patient was rated as negative for primary tumor,
that is, true CUP.
One expert reader, who was not part of the review boards,
finally defined presence and location of malignant and benign le-
sions in case histopathology was unavailable or clinical tests were
inconclusive. This reader was unblinded to all patient data, includ-
ing all available previous exams and follow-up exams.
Statistical Analysis
The sensitivity; specificity; positive predictive value; nega-
tive predictive value; accuracy for the detection of the primary site;
and detection of lymph node metastases and distant metastases on
PET/CT, PET/MR, CT, andMRwere calculated. The diagnostic ac-
curacy of each modality was assessed usingMcNemar test. The dif-
ference of diagnostic accuracy between PET/CT and PET/MR was
addressed using Wilcoxon signed-rank test. P < 0.05 was deemed
statistically significant. All statistical analyses used IBM SPSS
Statistics 19.0.0 (IBM, Armonk, NY).
RESULTS
Forty-three patients referred for whole-body staging underwent
PET/CT-MRI. The median time to imaging was 28 days (range,
6–214 days). PET/CTacquisition took 20 ± 2minutes (mean ± SD),
and MR acquisition took 21 ± 5 minutes. The mean administered
dosage was 268 ± 66 MBq.
Initial patient characteristics, reasons for referral, and initial
histopathology (if available) are given in Table 1. Eleven of the
CUP patients with cervical lymphadenopathy had lymph node re-
section before inclusion into the study. Presence and location of pri-
mary tumors according to the standard of reference are given in
Table 2. Thirty (69.8%) of 43 patients had malignant disease. Accu-
racy of PET/CT, PET/MR, CT, andMRI are given in Tables 3 and 4.
Details about misdiagnoses with both modalities are given in
Table 5. PET/MR was significantly superior to PET/CT in the de-
tection of the primary site (P = 0.020). The same applied to MR
and CT (P = 0.011).
Primary Site
PET/CT detected a primary tumor in 9 (30%) of 30 patients
with malignant disease, and PET/MR in 11 (36.7%) of 30. PET/
CT readers incorrectly classified 5 sites of physiologic FDG uptake
(2 larynx, nasopharynx, tonsil, and rectum) as primary site. One
Tornwaldt cyst with FDG uptake was mistaken for a primary naso-
pharyngeal carcinoma. PET/CT also misclassified several malig-
nant lesions: One patient with squamous cell CUP metastatic to
the bone, lung, and skin was misclassified as metastasizing skin
cancer. In another patient, a lung metastasis was misdiagnosed as
primary lung cancer. One primary cholangiocarcinomawas mistaken
for a liver metastasis. One kidney metastasis from primary lung
carcinoma was mistaken for a primary renal cell carcinoma. In
1 patient, retroperitoneal Castleman disease with renal infiltration
was mistaken for a primary renal cell carcinoma with retroperito-
neal lymph node metastasis. In another patient, a small appendix
carcinoma was missed, whereas the coexisting pseudomyxoma
was mistaken for ascites of unknown etiology.
PET/MR readers incorrectly diagnosed one lung metastasis
as primary bronchial carcinoma, one T1 nasopharyngeal carcinoma
TABLE 2. Final Diagnosis
Primary lesions
Malignant (n = 30, 69.8%)
Unknown 16 (37%)
Head and neck cancer 3 (7%)
Lung cancer 3 (7%)
Cholangiocarcinoma 2 (5%)
Liver carcinoma 1 (2%)
Appendix carcinoma 1 (2%)
Vaginal carcinoma 1 (2%)
Paraganglioma 1 (2%)
Hodgkin disease 1 (2%)
Castleman disease* 1 (2%)
Benign (n = 13, 30.2%)
Idiopathic lymphadenopathy 4 (9%)
Sarcoidosis 2 (5%)
Viral infection 2 (5%)
Multiple sclerosis 1 (2%)
Multiple system atrophy 1 (2%)
Adrenal adenoma 1 (2%)
Inflammatory lung nodule 1 (2%)
Idiopathic tumor marker elevation 1 (2%)
Lymph node metastases (region involved, patient-based)
Cervical 6 (14%)
Periportal 1 (2%)
Retroperitoneal 1 (2%)
Inguinal 1 (2%)
Mediastinal + hilar 3 (7%)
Cervical + mediastinal + hilar 1 (2%)
Axillary + mediastinal + hilar 1 (2%)
Cervical + axillary + mediastinal + hilar 1 (2%)
No malignant nodal disease 28 (65%)
Distant metastases (organ or site involved, patient-based)
Lung 1 (2%)
Liver 2 (5%)
Bone 3 (7%)
Lung + liver 1 (2%)
Lung + muscle 1 (2%)
Spleen + muscle 1 (2%)
Lung + liver + muscle 1 (2%)
Retroperitoneum + bone + muscle 1 (2%)
No distant metastasis 32 (74%)
*Because Castleman disease is a lymphoproliferative disorder of unknown etiol-
ogy with clinical features and treatment options similar to malignant lymphoma, it
was summarized under malignant.
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as physiologic FDG uptake, and one retroperitoneal paraganglioma
as lymph node metastasis from CUP.
Lymph Node Metastases
In addition to the points listed previously, both PET/CT and
PET/MR readers missed one biopsy-proven inguinal lymph node
metastasis due to low FDG uptake.
Distant Metastases
In addition to the results mentioned previously, PET/CT
readers missed one liver metastasis due to low FDGuptake andmis-
took one lung metastasis for an inflammatory infiltrate. In a patient
with paraneoplastic symptoms, PET/MR readers misclassified one
FDG-avid pituitary adenoma as hypophysitis.
Impact of PET Component on CT and MR
The PET component added value to both CTandMRI for the
correct diagnosis, particularly with regard to the sensitivity for dis-
tant metastasis (Tables 3 and 4).
Representative cases are given in Figures 1 and 2.
We grouped all 22 false positives (FP) and false negatives
(FN) into 4 categories according to the reason of misdiagnosis
(Table 5). Nine (40.9%) of 22misdiagnoses were due to physiologic
or benign FDG uptake, most of them were head and neck lesions
(5 of 9; 55.5%). In this category, PET/MR was superior to PET/CT
TABLE 3. Diagnostic Accuracy of EachModality for 43 Patients
(Numerical Display)
Primary Tumor
Lymph Node
Metastasis
Distant
Metastasis
PET/CT TP 9 14 9
TN 22 26 32
FP 8 2 0
FN 4 1 2
PET/MR TP 11 14 11
TN 29 28 31
FP 1 0 1
FN 2 1 0
CT TP 7 13 3
TN 23 24 30
FP 7 4 2
FN 6 2 8
MRI TP 9 13 6
TN 29 28 29
FP 1 0 3
FN 4 2 5
TP indicates true positive; FP, false positive; FN, false negative; TN, true negative.
TABLE 4. Diagnostic Accuracy of Each Modality for 43 Patients (Percentage Display)
Primary Tumor Lymph Node Metastasis Distant Metastasis
PET/CT Accuracy 0.72 (0.59–0.82) 0.93 (0.82–0.97) 0.95 (0.86–0.95)
Sensitivity 0.69 (0.47–0.86) 0.93 (0.77–0.99) 0.82 (0.63–0.82)
Specificity 0.73 (0.64–0.81) 0.93 (0.84–0.96) 1.00 (0.94–1.00)
PPV 0.53 (0.36–0.66) 0.88 (0.72–0.93) 1.00 (0.77–1.00)
NPV 0.85 (0.73–0.93) 0.96 (0.87–0.99) 0.94 (0.88–0.94)
P 0.388 1.000 0.500
PET/MR Accuracy 0.93 (0.82–0.97) 0.98 (0.88–0.98) 0.98 (0.89–0.98)
Sensitivity 0.85 (0.66–0.91) 0.93 (0.80–0.93) 1.00 (0.82–1.00)
Specificity 0.97 (0.89–0.99) 1.00 (0.93–1.00) 0.97 (0.91–0.97)
PPV 0.92 (0.72–0.98) 1.00 (0.86–1.00) 0.92 (0.75–0.92)
NPV 0.94 (0.86–0.96) 0.97 (0.90–0.97) 1.00 (0.94–1.00)
P 1.000 1.000 1.000
CT Accuracy 0.70 (0.57–0.81) 0.86 (0.73–0.92) 0.77 (0.69–0.83)
Sensitivity 0.54 (0.33–0.73) 0.87 (0.76–0.91) 0.27 (0.11–0.40)
Specificity 0.77 (0.67–0.85) 0.86 (0.76–0.91) 0.94 (0.88–0.98)
PPV 0.50 (0.30–0.67) 0.76 (0.60–0.85) 0.60 (0.25–0.88)
NPV 0.79 (0.70–0.88) 0.92 (0.82–0.98) 0.79 (0.74–0.83)
P 1.000 0.687 0.109
MR Accuracy 0.88 (0.77–0.92) 0.95 (0.85–0.95) 0.81 (0.70–0.90)
Sensitivity 0.69 (0.50–0.76) 0.87 (0.72–0.87) 0.55 (0.32–0.70)
Specificity 0.97 (0.89–0.99) 1.00 (0.92–1.00) 0.91 (0.83–0.96)
PPV 0.90 (0.65–0.98) 1.00 (0.84–1.00) 0.67 (0.39–0.86)
NPV 0.88 (0.80–0.90) 0.93 (0.86–0.93) 0.85 (0.78–0.90)
P 0.375 0.500 0.727
PET/CT vs PET/MR P (Wilcoxon) 0.020 0.157 0.564
CT vs MR 0.011 0.046 0.480
PET/CT vs CT 0.665 0.083 0.005
PET/MR vs MR 0.317 0.317 0.020
NPV indicates negative predictive value; PPV, positive predictive value. P values are given for comparison of either modality with standard of reference and for comparison of
both modalities.
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(1 FP vs 8 FP). Seven (31.8%) of 22 misdiagnoses were due to
confusion of primary sites and metastases, and vice versa.
DISCUSSION
This preliminary study compared the diagnostic accuracy of
PET/MR and PET/CT in patients with suspected occult malignan-
cies. PET/MRwas superior to PET/CT in the assessment of primary
tumors. Therewas no significant difference between bothmodalities
in the assessment of lymph node metastases and distant metastases.
This study was performed on a trimodality PET/CT-MR sys-
tem consisting of 2 linked scanners. This system generates PET/CT
and PET/MR datasets using identical PET data in each patient. This
allows for an exact comparison of hybrid datasets, whereas compar-
isons might be limited when using 2 independent scanners. In gen-
eral, tumor to normal tissue contrast increases in the time course
after FDG injection and until significant decay occurs.22 Also, sepa-
rate scanners would use PET detectors with different sensitivity, and
the comparably less accurate attenuation correction on PET/MR
would impair a fair comparison of both modalities.23–25 Therefore,
TABLE 5. Reasons for Misdiagnosis (n = 22)
Physiologic/benign FDG uptake misdiagnosed as malignant lesion (n = 9, 40.9%)
PET/CT 8 (2 Nasopharynx, 2 larynx, oropharynx, kidney, rectum, para-aortic lymph node)
PET/MR 1 (Pituitary adenoma)
Metastatic lesion with FDG uptake misdiagnosed as primary site, or vice versa (n = 7, 31.8%)
PET/CT 5 (Subcutaneous metastasis, lung metastasis, kidney metastasis, retroperitoneal Castleman disease, primary cholangiocarcinoma)
PET/MR 2 (Lung metastasis, primary retroperitoneal paraganglioma)
Malignant lesion missed due to subtle FDG uptake (n = 4, 18.2%)
PET/CT 3 (Appendix carcinoma, liver metastasis, inguinal lymph node metastasis)
PET/MR 1 (Inguinal lymph node metastasis)
Malignant lesion with FDG uptake misdiagnosed as physiologic/benign (n = 2, 9.0%)
PET/CT 1 (Lung metastasis)
PET/MR 1 (Nasopharyngeal carcinoma)
FIGURE 1. A 57-year-old woman with CUP manifesting as squamous cell carcinoma in cervical lymph nodes. CT image (A),
T2-weighted MR image (B), and fused PET images corresponding to images A and B (C and D, respectively) were obtained.
Fused images (C and D) show an FDG-avid lesion in the fossa of Rosenmüller (arrows), a place where occult nasopharyngeal
carcinoma is sometimes located. On the CT image (A), no anatomical abnormality is seen (arrows); however, ruling out a
tumor is difficult. On the MR image (B), mucosa, fat, and muscle tissue are clearly differentiated (arrows), which is helpful to
assign the FDG uptake to normal tissue. After the exam, the fossa was verified to be normal by panendoscopy. Especially in the
head and neck, physiologic FDG uptake may lead to false positives and may provoke unnecessary biopsy or delay of treatment.
Unlike CT, MR provided complementary information for PET in this case.
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the approach used in our study eliminates several unknowns that
might interfere when correlating both modalities.
In CUP patients, the most prevalent site of occult primaries
is the head and neck region.5 There, PET/CT is known to be more
sensitive than contrast-enhanced CT or MRI.11 However, physio-
logic uptake in normal tissue (eg, palatine tonsils, vocal cords)
on PET/CT sometimes confounds image interpretation.26,27 CT
is limited in these areas because of intrinsic low soft tissue con-
trast. Our study indicates that MR might be more specific and be
able to rule out malignancy in regions with high FDG uptake. This
might help prevent unnecessary biopsy and delay of diagnosis.
Five of 8 false-positive findings on PET/CT were located in the
neck, whereas PET/MR was not compromised by false positives
in this region. A recent study with 56 CUP patients with cervical
lymph node metastases yielded a sensitivity and specificity of
PET/CTof 0.69 and 0.88, respectively.11 The discrepancy of these
results to our study is likely due to differences in the patient cohort,
with different previous diagnostic workup. Only 3 (17%) of 18 patients
with suspected cervical CUP (17 malignant cervical lymphadenop-
athy and 1 neck mass) finally had a verified primary site in the head
and neck in our study, compared with 32 (56%) of 57 patients in the
aforementioned study. Different study designs and inhomogeneous
patient samples, partly because of the inhomogeneous nature of the
study subject itself, are an inherent problem for comparing diag-
nostic accuracies. Thus, one meta-analysis of 16 studies reported
a great variation of the performance of FDG-PET (sensitivity,
0.33–1.00; specificity, 0.40–1.00).28
Our results are also interesting from another point of view.
One recent study showed that combined contrast-enhanced CT
and MRI was not superior to contrast-enhanced CT alone in CUP
patients, whereas PET/CT performed better than both CT-MR and
CT.11 This is in line with our results. Our study shows that PET/
MR is also superior to MR alone. Additionally, our study indicates
that MR might be a better complementary anatomical imaging mo-
dality in combination with PET than CT. Besides, we found that the
addition of PET enhances the performance of both CT and MR in
detecting distant metastases but not in detecting primary tumors
and lymph node metastases. On the other hand, MR was superior
to CT only in the detection of primary tumors. These results are in
line with previously published work on CUP.2,5,11,29
A meta-analysis of 433 CUP patients found a primary tumor
detection rate of 37% with PET/CT, which is comparable to our
study.5 However, the sensitivity/specificity of PET/CT in our study
was slightly inferior to this meta-analysis (0.69/0.73 vs 0.84/0.84).
In our cohort, there were 4 patients with malignant lung le-
sions. Three of them were correctly diagnosed with PET/CT and
two with PET/MR. Although there was no critical disadvantage
of PET/MR in the detection of lung lesions in our study, an accu-
rate assessment of lung malignancies represents one big challenge
for PET/MR in general.30 One possible solution currently available
FIGURE 2. A 61-year-old woman with suspected ascites of unknown cause. Maximum intensity projection PET image (A),
axial CT images (B, F), axial T2-weighted MR image with periodically rotated overlapping parallel lines with enhanced
reconstructionmethod (PROPELLER) (C), axial T1-weightedMR imagewith fat suppression using theDixonmethod (IDEAL) (G),
and PET images (D, H, E, and I) corresponding to each image B, F, C, andG, respectively. Both PET with low FDG uptake and
CT with homogeneous fluid density do not provide specific information for the cause of suspected ascites (arrows on B and D).
On MR images, several septations are seen within the fluid, indicating loculated gelatinous ascites due to neoplastic cause
rather than simple ascites (arrows on C and E). This feature, along with homogeneous hyperintensity and shear amount of the
fluid, correctly suggested pseudomyxoma peritonei on PET/MR. Although the focal FDG uptake at the level of the ileocecal
junction (arrow on H) was misinterpreted as unspecific small bowel uptake on PET/CT, PET/MR visualized the appendix and
correctly suggested primary mucinous neoplasm of the appendix (I, arrows). Here, PET and MR provided complementary
information both for the primary site and distant metastatic disease. The patient underwent right-sided hemicolectomy, and the
diagnosis was verified by histopathology.
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is special MR sequences for the lung (eg, ultra-short TE sequences,
respiratory-gated T2-weighted sequences).14,31 However, such
special sequences require additional scanning time (approximately
5 minutes). In a clinical setup, the total scan time is usually limited,
both as a matter of patient convenience and patient throughput.
Several studies evaluated the natural history and clinical im-
pact of lung lesions missed on PET/MR. Roy et al evaluated the
outcome of 89 non-FDG-avid lung nodules missed on PET/MR
in 43 oncological patients.32 Only 3 of 89 nodules in only 1 patient
progressed, whereas the rest resolved or remained stable during
3 years of follow-up. Hence, the vast majority of non FDG-avid
lung nodules is probably clinically irrelevant. Although further
studies are needed, the clinical drawback of PET/MR in the lung
might be less critical than expected.
PET/MR might improve the clinical workflow by replac-
ing PET/CT and MRI in CUP patients. CT imaging might ensue
if needed. This approach might minimize a delay of imaging ex-
amination that is known to worsen the outcome in patients with
advanced malignancies such as CUP. Although the clinical
workflowwas not a goal of our study, our results seem to justify that
PET/MR might replace PET/CT in patients with suspected
occult malignancies.
Limitations
A first limitation of our study is that histopathological or sur-
gical verification was not available for all lesions, for ethical rea-
sons. This represents an intrinsic limitation because surgery is
often precluded in metastasized tumors. Second, our study sample
is too small to provide further subanalysis of body regions. Third,
the acquired MR sequences were inhomogeneous. Sequences were
selected depending on suspected locations of primary tumors, if
possible, only being limited by the PET acquisition time, and thus
matching the PET/CT acquisition time to allow for a fair compari-
son. All such dedicated sequences were conventional ones and did
not include advanced MR techniques such as diffusion-weighted
imaging with specialized technique (eg, reduced volume excitation,
segmented readout) or MR perfusion. If the choice of regionalized
sequences is improved in the future, the diagnostic accuracy of
PET/MR in this situation is expected to be at least comparable to
our study. Fourth, MR using several pulse sequences was com-
pared with CT. However, contrast was administered for both MR
and CT in the same patients, and MR acquisition time fairly
matched PET/CTacquisition time. Fifth, previously performed clin-
ical and imaging examinations represent some sort of inclusion
bias for our study, which, however, cannot be avoided in patients
with occult malignancies. The same bias existed for both PET/
CT and PET/MR and thus does not impact on a comparison of
both modalities. Sixth, approximately half of examinations were
without contrast. However, previous studies revealed that the ad-
ministration of contrast does not increase the accuracy of PET/
CT in CUP patients.5 Seventh, the studied population has a poten-
tial selection bias concerning the location of malignant lesions. In
almost half of the patients, lesions were located in body regions
where MR is supposedly superior to CT, for example, the head
and neck. However, this would represent an intrinsic bias because
the head and neck is the most common origin of CUP.33 Notably,
several studies have also shown equality of MR and CT in head
and neck tumors.11,34,35
In conclusion, PET/MR outperforms PET/CT in the workup
of patients with suspected occult malignancies, especially in those
with cervical disease. PET/MR was comparable to PET/CT in de-
tecting lymph nodemetastases and distant metastases. Our study in-
dicates that PET/MR might replace PET/CT in CUP patients to
improve clinical workflow.
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